MD3233862T2 - Derivați ai imidazopiridazinei în calitate de inhibitori ai pΙ3Κbeta - Google Patents
Derivați ai imidazopiridazinei în calitate de inhibitori ai pΙ3Κbeta Download PDFInfo
- Publication number
- MD3233862T2 MD3233862T2 MDE20170191T MD3233862T2 MD 3233862 T2 MD3233862 T2 MD 3233862T2 MD E20170191 T MDE20170191 T MD E20170191T MD 3233862 T2 MD3233862 T2 MD 3233862T2
- Authority
- MD
- Moldova
- Prior art keywords
- compounds
- inhibitors
- pι3κbeta
- imidazopyridazine derivatives
- relates
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000005233 imidazopyridazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- MJQSRSOTRPMVKB-UHFFFAOYSA-N 5h-imidazo[4,5-c]pyridazine Chemical group C1=NNC2=NC=NC2=C1 MJQSRSOTRPMVKB-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Taps Or Cocks (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199322 | 2014-12-19 | ||
| PCT/EP2015/080604 WO2016097347A1 (en) | 2014-12-19 | 2015-12-18 | IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3233862T2 true MD3233862T2 (ro) | 2019-11-30 |
Family
ID=52134002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20170191 MD3233862T2 (ro) | 2014-12-19 | 2015-12-18 | Derivați ai imidazopiridazinei în calitate de inhibitori ai pΙ3Κbeta |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10087187B2 (enExample) |
| EP (1) | EP3233862B1 (enExample) |
| JP (1) | JP6568588B2 (enExample) |
| KR (1) | KR20170095239A (enExample) |
| CN (1) | CN107108634B (enExample) |
| AU (1) | AU2015366190B2 (enExample) |
| BR (1) | BR112017012930A2 (enExample) |
| CA (1) | CA2967551A1 (enExample) |
| CY (1) | CY1122381T1 (enExample) |
| DK (1) | DK3233862T3 (enExample) |
| EA (1) | EA029789B1 (enExample) |
| ES (1) | ES2761051T3 (enExample) |
| HR (1) | HRP20191550T1 (enExample) |
| HU (1) | HUE045220T2 (enExample) |
| IL (1) | IL252866B (enExample) |
| LT (1) | LT3233862T (enExample) |
| MA (1) | MA41174B1 (enExample) |
| MD (1) | MD3233862T2 (enExample) |
| ME (1) | ME03517B (enExample) |
| MX (1) | MX2017008074A (enExample) |
| PL (1) | PL3233862T3 (enExample) |
| PT (1) | PT3233862T (enExample) |
| RS (1) | RS59301B1 (enExample) |
| SI (1) | SI3233862T1 (enExample) |
| SM (1) | SMT201900509T1 (enExample) |
| WO (1) | WO2016097347A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6912460B2 (ja) | 2015-10-09 | 2021-08-04 | ヤンセン ファーマシューティカ エヌ．ベー． | ＰＩ３Ｋβ阻害剤としてのキノキサリンおよびピリドピラジン誘導体 |
| JP7149854B2 (ja) | 2016-06-16 | 2022-10-07 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｉ３ｋ ｂｅｔａ阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体 |
| CN110461827A (zh) | 2017-03-29 | 2019-11-15 | 詹森药业有限公司 | 作为PI3K-β抑制剂的喹喔啉和吡啶并吡嗪衍生物 |
| JP7637328B2 (ja) | 2019-02-07 | 2025-02-28 | ベイジーン リミテッド | Ｔｌｒ７アゴニストとしてのイミダゾ［２，１－ｆ］［１，２，４］トリアジン－４－アミン誘導体 |
| CN110128505A (zh) * | 2019-05-21 | 2019-08-16 | 梯尔希（南京）药物研发有限公司 | 一种戈舍瑞林杂质的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| EP2046333A4 (en) | 2006-07-24 | 2010-09-15 | Glaxosmithkline Llc | THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE |
| JP2010502716A (ja) | 2006-09-07 | 2010-01-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | インターロイキン１受容体関連キナーゼの調節物質 |
| US20100305113A1 (en) * | 2007-05-09 | 2010-12-02 | Hans-Georg Capraro | Substituted Imidazopyridazines as Lipid Kinase Inhibitors |
| EP2217601A1 (en) | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
| KR20100128305A (ko) * | 2008-02-28 | 2010-12-07 | 노파르티스 아게 | Ｃ-ｍｅｔ 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-ｂ]피리다진 유도체 |
| WO2010007099A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| UA111579C2 (uk) | 2009-08-17 | 2016-05-25 | Інтеллікіне Ллк | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ |
| DE102009049679A1 (de) * | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| WO2011058109A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| PT2624696T (pt) | 2010-10-06 | 2017-03-21 | Glaxosmithkline Llc | Derivados de benzimidazole como inibidores da cinase pi3 |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| US9096605B2 (en) | 2011-08-24 | 2015-08-04 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors |
| US8906910B2 (en) | 2011-12-20 | 2014-12-09 | Glaxosmithkline Llc | Imidazopyridine derivatives as PI3 kinase |
| US8778937B2 (en) | 2011-12-20 | 2014-07-15 | Glaxosmithkline Llc | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors |
| TWI574962B (zh) * | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
-
2015
- 2015-12-18 JP JP2017532819A patent/JP6568588B2/ja not_active Expired - Fee Related
- 2015-12-18 LT LTEP15810784.7T patent/LT3233862T/lt unknown
- 2015-12-18 HU HUE15810784A patent/HUE045220T2/hu unknown
- 2015-12-18 US US15/537,551 patent/US10087187B2/en active Active
- 2015-12-18 AU AU2015366190A patent/AU2015366190B2/en not_active Ceased
- 2015-12-18 MD MDE20170191 patent/MD3233862T2/ro not_active IP Right Cessation
- 2015-12-18 DK DK15810784.7T patent/DK3233862T3/da active
- 2015-12-18 ME MEP-2019-263A patent/ME03517B/me unknown
- 2015-12-18 ES ES15810784T patent/ES2761051T3/es active Active
- 2015-12-18 RS RSP20191225 patent/RS59301B1/sr unknown
- 2015-12-18 CA CA2967551A patent/CA2967551A1/en active Pending
- 2015-12-18 SM SM20190509T patent/SMT201900509T1/it unknown
- 2015-12-18 CN CN201580069133.7A patent/CN107108634B/zh not_active Expired - Fee Related
- 2015-12-18 PT PT158107847T patent/PT3233862T/pt unknown
- 2015-12-18 WO PCT/EP2015/080604 patent/WO2016097347A1/en not_active Ceased
- 2015-12-18 MX MX2017008074A patent/MX2017008074A/es active IP Right Grant
- 2015-12-18 SI SI201530855T patent/SI3233862T1/sl unknown
- 2015-12-18 KR KR1020177016722A patent/KR20170095239A/ko not_active Ceased
- 2015-12-18 EA EA201791396A patent/EA029789B1/ru not_active IP Right Cessation
- 2015-12-18 EP EP15810784.7A patent/EP3233862B1/en active Active
- 2015-12-18 HR HRP20191550 patent/HRP20191550T1/hr unknown
- 2015-12-18 PL PL15810784T patent/PL3233862T3/pl unknown
- 2015-12-18 MA MA41174A patent/MA41174B1/fr unknown
- 2015-12-18 BR BR112017012930A patent/BR112017012930A2/pt active Search and Examination
-
2017
- 2017-06-13 IL IL252866A patent/IL252866B/en active IP Right Grant
-
2019
- 2019-10-03 CY CY20191101031T patent/CY1122381T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE045220T2 (hu) | 2019-12-30 |
| KR20170095239A (ko) | 2017-08-22 |
| JP6568588B2 (ja) | 2019-08-28 |
| PL3233862T3 (pl) | 2020-01-31 |
| MA41174A (fr) | 2017-10-25 |
| BR112017012930A2 (pt) | 2018-01-09 |
| EP3233862B1 (en) | 2019-07-03 |
| CY1122381T1 (el) | 2021-01-27 |
| IL252866B (en) | 2020-09-30 |
| WO2016097347A1 (en) | 2016-06-23 |
| LT3233862T (lt) | 2019-09-10 |
| IL252866A0 (en) | 2017-08-31 |
| DK3233862T3 (da) | 2019-10-07 |
| EA029789B1 (ru) | 2018-05-31 |
| CN107108634A (zh) | 2017-08-29 |
| EA201791396A1 (ru) | 2017-10-31 |
| EP3233862A1 (en) | 2017-10-25 |
| MX2017008074A (es) | 2018-01-09 |
| PT3233862T (pt) | 2019-10-09 |
| AU2015366190A1 (en) | 2017-05-25 |
| CA2967551A1 (en) | 2016-06-23 |
| ES2761051T3 (es) | 2020-05-18 |
| ME03517B (me) | 2020-04-20 |
| SI3233862T1 (sl) | 2019-09-30 |
| CN107108634B (zh) | 2020-09-15 |
| US20180002336A1 (en) | 2018-01-04 |
| US10087187B2 (en) | 2018-10-02 |
| SMT201900509T1 (it) | 2019-11-13 |
| RS59301B1 (sr) | 2019-10-31 |
| HRP20191550T1 (hr) | 2019-11-29 |
| AU2015366190B2 (en) | 2020-01-23 |
| MA41174B1 (fr) | 2019-09-30 |
| JP2017538734A (ja) | 2017-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX375484B (es) | Derivados de azabencimidazol como inhibidores de pi3k beta | |
| PH12017502001A1 (en) | Amido-substituted cyclohexane derivatives | |
| MD3405471T2 (ro) | Noi derivați de amoniu, procedeu pentru prepararea acestora și compoziții farmaceutice care îi conțin | |
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| EA201692003A1 (ru) | Макроциклические производные пиримидина | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201692000A1 (ru) | Макроциклические производные пиридина | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| MX2020005079A (es) | Derivados de aminotiazol utiles como agentes antiviricos. | |
| MD3233862T2 (ro) | Derivați ai imidazopiridazinei în calitate de inhibitori ai pΙ3Κbeta | |
| EA201500931A1 (ru) | Производные пиридин-4-ила | |
| EA201890906A1 (ru) | ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| EA201691962A1 (ru) | Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2 | |
| MD3303331T2 (ro) | Modulatori alosterici pozitivi ai receptorilor muscarinici M1 | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| UY35785A (es) | Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1) | |
| PH12017501336A1 (en) | Preventive and/or therapeutic agent of immune disease | |
| EA201791397A1 (ru) | СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| EA201690797A1 (ru) | Новые соединения | |
| EA201690236A1 (ru) | Производные индол-3-карбинола | |
| EA201990046A1 (ru) | Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| MX2014005414A (es) | Derivados de 2-carboxamida-cicloamino-urea para su uso en el tratamiento de las enfermedades dependientes del factor de crecimiento endotelial vascular (vegf). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |